Articles tagged with 'Export-TopNews' & 'Export-LatestNews' & 'only-PressPage' | Bayer

Late-stage development programs with significant potential to drive long-term growth / New R&D strategy and operating model sharpening innovation focus and strengthening early development pipeline in oncology, cardiovascular, neurology & rare disease...

Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline / Fifth major cl...

Holistic approach to improve water use and quality across the entire value chain and contribute to an impactful change / Integration of water stewardship in business and investment decisions / Shaping a water-resilient agriculture system with key con...

Nubeqa™ now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer / Additional indication based on data from the pivotal Phase III ARASENS trial ...

Ready-to-use AgPowered Services from Bayer running on the new Microsoft Azure Data Manager for Agriculture / Readymade capabilities and robust digital infrastructure allow innovators to focus on differentiated value / Companies, farmers and consumers...

Rune Labs’ StriveStudy platform and Emerald Innovations’ Emerald wireless monitoring sensor will passively capture data on Parkinson’s disease impact on function of fifty study participants in BlueRock’s global non-interventional clinical study.  / C...

Research Triangle Park, N.C.– March 9, 2023 – Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, today announced that Gustavo Pesquin will become the company’s next Chief Executive Officer (C...

Basel, Switzerland, March 7, 2023 — A first-of-its-kind collaboration in the consumer health industry is developing a platform aimed at reducing or replacing animal testing using “organ-on-chip” (OoC) technology and interactive computational software...

In the prospective observational XARENO study, after a two year follow up period, Xarelto was associated with a reduced risk of adverse kidney outcomes and all-cause mortality in patients with non-valvular atrial fibrillation (NVAF) and advanced chro...

European Commission granted approval of Nubeqa™ (darolutamide) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) / Approval is based on Phase III ARASENS trial data...

Submission to the Ministry of Health, Labor, and Welfare (MHLW) in Japan for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of phase III clinical trials, PUL...

Group sales increase 8.7 percent (Fx & portfolio adj.) to 50.739 billion euros / EBITDA before special items rises 20.9 percent to 13.513 billion euros, largely driven by exceptionally strong performance at Crop Science / Pharmaceuticals increases sa...

Presskit

LGMD is a Rare Form of Muscular Dystrophy with No Approved Therapies

Agnes Binagwaho, Dante Pesce and Jeffrey Ubben appointed to independent Sustainability Council / New personnel enhance the council’s subject matter expertise in key focus areas such as access to medicine, human rights and sustainable finance / Brauli...

Darolutamide approved for metastatic prostate cancer as well as non-metastatic castration-resistant prostate cancer / New approval based on data from the pivotal Phase III ARASENS trial 

The Nutrient Gap Initiative, aiming to improve access to essential nutrients for 50 million people by 2030, expands its scope to include both supplementation and food

Featured presentations include development compound gadoquatrane, a novel contrast agent for MRI / Further research explores potential of AI and digital advances in medical imaging 

New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS) and improved key clinically relevant endpoints in patients with various t...

Closing follows announcement of acquisition on January 18, 2023 / Acquisition bolsters Bayer’s position in digital medical imaging / Blackford will utilize Bayer’s well established “arm’s length” operating model to preserve the company’s entrepreneur...

European Commission granted approval for a label update to extend the indication of Kerendia™ to early stages of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) and to include findings from the Phase III FIGARO-DKD cardiovascular (...

Leverkusen, February 8, 2023 – The Supervisory Board of Bayer AG has appointed Bill Anderson to become CEO of Bayer, effective June 1, 2023. He will join Bayer as a member of the Board of Management on April 1, 2023. Bill Anderson was elected unanimo...

Bayer provides 1 million euros for immediate aid to Türkiye via the disaster relief organizations Red Crescent and Ahbap as well as 200.000 euros to Syria via the German Red Cross / A global employee donation campaign for both Türkiye and Syria will ...

Partnering with players along the food value chain is key to tackle challenges of food security and climate change / Bayer makes substantial progress in accelerating development of biologicals through collaborations with Ginkgo Bioworks, Kimitec and ...

Filing for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of clinical trials, PULSAR and PHOTON / In both trials, aflibercept 8 mg demonstrated unprecedented...

Both companies enter into a global strategic partnership for Biologicals discovery and commercialization, that includes crop protection and biostimulant products based on molecules derived from natural sources / Kimitec becomes a new strategic partne...

The Professor at the Institute of Organic Chemistry at the University of Münster receives the award in recognition of his groundbreaking work / Professor Antje Boetius, Director of the Alfred Wegener Institute (AWI) in Bremerhaven, is presented with ...

Biological pheromones present a non-toxic, innovative opportunity for biological crop protection while safeguarding biodiversity and beneficial pollinators / M2i’s patented bio-sourced micro-encapsulation technology means long-lasting pheromone contr...

CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5% compared to ADT with docetaxel alone, with sim...

Jeffrey Hatfield becomes Chairman of the Board of Directors at Vividion Therapeutics